Already have an account? Sign in.
Evercore ISI Initiates Street-High Price Target for CoreWeave
CoreWeave received an Outperform rating and a $175 price target from Evercore ISI.
CoreWeave received an Outperform rating and a $175 price target from Evercore ISI.
Corbus Pharmaceuticals gets Buy rating ($45 target). Drug CRB-701 shows strong cancer results, safer than rivals. Stock down 43% may be opportunity.
Booking beat earnings with strong growth, despite Middle East impact; expects modest Q2 and recovery later in 2026.
NXP Semiconductors beat earnings, demand is rising again, and forecasts are strong—shares surged on optimistic outlook.